HEALEY ALS Platform Trial Regimen I expands to 240 participants

Highlights: Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements Increase in sample size driven by enrolment rate exceeding original expectations...